IBDEI0ZJ ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17327,0)
 ;;=V69.3^^88^1062^2
 ;;^UTILITY(U,$J,358.3,17327,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17327,1,4,0)
 ;;=4^V69.3
 ;;^UTILITY(U,$J,358.3,17327,1,5,0)
 ;;=5^GAMBLING & BETTING
 ;;^UTILITY(U,$J,358.3,17327,2)
 ;;=^303475
 ;;^UTILITY(U,$J,358.3,17328,0)
 ;;=V69.8^^88^1062^4
 ;;^UTILITY(U,$J,358.3,17328,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17328,1,4,0)
 ;;=4^V69.8
 ;;^UTILITY(U,$J,358.3,17328,1,5,0)
 ;;=5^SELF-DAMAGING BEHAVIOR
 ;;^UTILITY(U,$J,358.3,17328,2)
 ;;=^303476
 ;;^UTILITY(U,$J,358.3,17329,0)
 ;;=V65.42^^88^1062^1
 ;;^UTILITY(U,$J,358.3,17329,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17329,1,4,0)
 ;;=4^V65.42
 ;;^UTILITY(U,$J,358.3,17329,1,5,0)
 ;;=5^COUNSEL-SUBS USE/ABUSE
 ;;^UTILITY(U,$J,358.3,17329,2)
 ;;=^303467
 ;;^UTILITY(U,$J,358.3,17330,0)
 ;;=V68.89^^88^1063^1
 ;;^UTILITY(U,$J,358.3,17330,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17330,1,4,0)
 ;;=4^V68.89
 ;;^UTILITY(U,$J,358.3,17330,1,5,0)
 ;;=5^ADMIN ENC-ADV DIREC/LTC
 ;;^UTILITY(U,$J,358.3,17330,2)
 ;;=^295588
 ;;^UTILITY(U,$J,358.3,17331,0)
 ;;=V01.1^^88^1064^7
 ;;^UTILITY(U,$J,358.3,17331,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17331,1,4,0)
 ;;=4^V01.1
 ;;^UTILITY(U,$J,358.3,17331,1,5,0)
 ;;=5^TUBERCULOSIS CONTACT
 ;;^UTILITY(U,$J,358.3,17331,2)
 ;;=^295158
 ;;^UTILITY(U,$J,358.3,17332,0)
 ;;=V01.3^^88^1064^6
 ;;^UTILITY(U,$J,358.3,17332,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17332,1,4,0)
 ;;=4^V01.3
 ;;^UTILITY(U,$J,358.3,17332,1,5,0)
 ;;=5^SMALLPOX CONTACT
 ;;^UTILITY(U,$J,358.3,17332,2)
 ;;=^295160
 ;;^UTILITY(U,$J,358.3,17333,0)
 ;;=V01.4^^88^1064^5
 ;;^UTILITY(U,$J,358.3,17333,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17333,1,4,0)
 ;;=4^V01.4
 ;;^UTILITY(U,$J,358.3,17333,1,5,0)
 ;;=5^RUBELLA CONTACT
 ;;^UTILITY(U,$J,358.3,17333,2)
 ;;=^295161
 ;;^UTILITY(U,$J,358.3,17334,0)
 ;;=V01.5^^88^1064^4
 ;;^UTILITY(U,$J,358.3,17334,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17334,1,4,0)
 ;;=4^V01.5
 ;;^UTILITY(U,$J,358.3,17334,1,5,0)
 ;;=5^RABIES CONTACT
 ;;^UTILITY(U,$J,358.3,17334,2)
 ;;=^295162
 ;;^UTILITY(U,$J,358.3,17335,0)
 ;;=V01.6^^88^1064^8
 ;;^UTILITY(U,$J,358.3,17335,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17335,1,4,0)
 ;;=4^V01.6
 ;;^UTILITY(U,$J,358.3,17335,1,5,0)
 ;;=5^VENEREAL DIS CONTACT
 ;;^UTILITY(U,$J,358.3,17335,2)
 ;;=^295163
 ;;^UTILITY(U,$J,358.3,17336,0)
 ;;=V01.79^^88^1064^9
 ;;^UTILITY(U,$J,358.3,17336,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17336,1,4,0)
 ;;=4^V01.79
 ;;^UTILITY(U,$J,358.3,17336,1,5,0)
 ;;=5^VIRAL DIS CONTACT NEC
 ;;^UTILITY(U,$J,358.3,17336,2)
 ;;=^331577
 ;;^UTILITY(U,$J,358.3,17337,0)
 ;;=V01.81^^88^1064^2
 ;;^UTILITY(U,$J,358.3,17337,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17337,1,4,0)
 ;;=4^V01.81
 ;;^UTILITY(U,$J,358.3,17337,1,5,0)
 ;;=5^CONTACT/EXPOSURE TO ANTHRAX
 ;;^UTILITY(U,$J,358.3,17337,2)
 ;;=^328701
 ;;^UTILITY(U,$J,358.3,17338,0)
 ;;=V01.82^^88^1064^3
 ;;^UTILITY(U,$J,358.3,17338,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17338,1,4,0)
 ;;=4^V01.82
 ;;^UTILITY(U,$J,358.3,17338,1,5,0)
 ;;=5^EXPOSURE TO SARS
 ;;^UTILITY(U,$J,358.3,17338,2)
 ;;=^329963
 ;;^UTILITY(U,$J,358.3,17339,0)
 ;;=V01.89^^88^1064^1
 ;;^UTILITY(U,$J,358.3,17339,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17339,1,4,0)
 ;;=4^V01.89
 ;;^UTILITY(U,$J,358.3,17339,1,5,0)
 ;;=5^CONT/EXP TO OTHER COMM DISEASE
 ;;^UTILITY(U,$J,358.3,17339,2)
 ;;=^328661
 ;;^UTILITY(U,$J,358.3,17340,0)
 ;;=V02.60^^88^1065^6
 ;;^UTILITY(U,$J,358.3,17340,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17340,1,4,0)
 ;;=4^V02.60
 ;;^UTILITY(U,$J,358.3,17340,1,5,0)
 ;;=5^VIRAL HEPATITIS CARRIER, UNSPE
 ;;
 ;;$END ROU IBDEI0ZJ
